BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30679824)

  • 1. Eltrombopag for post-transplant cytopenias due to poor graft function.
    Marotta S; Marano L; Ricci P; Cacace F; Frieri C; Simeone L; Trastulli F; Vitiello S; Cardano F; Pane F; Risitano AM
    Bone Marrow Transplant; 2019 Aug; 54(8):1346-1353. PubMed ID: 30679824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag.
    Tang C; Chen F; Kong D; Ma Q; Dai H; Yin J; Li Z; Chen J; Zhu X; Mao X; Wu D; Tang X
    J Hematol Oncol; 2018 Aug; 11(1):103. PubMed ID: 30115080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation.
    Fu H; Zhang X; Han T; Mo X; Wang Y; Chen H; Han W; Wang J; Wang F; Yan C; Zhang Y; Sun Y; Liu K; Huang X; Xu L
    Bone Marrow Transplant; 2019 Aug; 54(8):1310-1318. PubMed ID: 30664724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children.
    Ali S; Gassas A; Kirby-Allen M; Krueger J; Ali M; Schechter T
    Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28653480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience.
    Kilic Gunes E; Yigit Kaya S; Yaman F; Yeniay MK; Vural K; Comert M; Sevindik OG; Andic N; Dagdas S; Nizam Ozen I; Kaynar L; Yavasoglu F; Ozet G; Karakus V; Ayli M
    Leuk Res; 2024 May; 140():107484. PubMed ID: 38520796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study.
    Giammarco S; Sica S; Chiusolo P; Laurenti L; Sorá F; Martino M; Metafuni E; Busca A; Risitano A; Vallejo C; Bacigalupo A
    Int J Hematol; 2021 Aug; 114(2):228-234. PubMed ID: 33886103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Eltrombopag for refractory thrombocytopenia in patients with allogeneic hematopoietic stem cell transplantation].
    Ma YR; Huang XJ; Mo XD; Han W; Yan CH; Chen Y; Ji Y; Chen YY; Wang Y; Zhang XH; Liu KY; Xu LP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1065-1069. PubMed ID: 28088971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of eltrombopag for the treatment of poor graft function after hematopoietic stem cell transplantation in children.
    Uria-Oficialdegui ML; Alonso L; Benitez-Carabante MI; Renedo B; Oliveras M; Diaz-de-Heredia C
    Pediatr Transplant; 2021 Jun; 25(4):e14010. PubMed ID: 33742757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience.
    Çekdemir D; Güvenç S; Özdemirkıran F; Eser A; Toptaş T; Özkocaman V; Haydaroğlu Şahin H; Ermiş Turak E; Esen R; Cömert M; Sadri S; Aslaner M; Uncu Ulu B; Karakuş A; Selim Bapur D; Alacacıoğlu İ; Aydın D; Tekinalp A; Namdaroğlu S; Ceran F; Tarkun P; Kiper D; Çetiner M; Yenerel M; Demir AM; Yılmaz G; Terzi H; Atilla E; Malkan ÜY; Acar K; Öztürk E; Tombak A; Sunu C; Salim O; Alayvaz N; Sayan Ö; Ozan Ü; Ayer M; Gökgöz Z; Andıç N; Kızılkılıç E; Noyan F; Özen M; Pepedil Tanrıkulu F; Alanoğlu G; Özkan HA; Aslan V; Çetin G; Akyol Erikçi A; Deveci B; Ersoy Dursun F; Dermenci H; Aytan P; Gündüz M; Karakuş V; Özlü C; Demircioğlu S; Akay Yanar OM; Özatlı D; Ündar L; Tiftik EN; Türköz Sucak AG; Haznedaroğlu İ; Özcan M; Şencan M; Tombuloğlu M; Özet G; Bilgir O; Turgut B; Özcan MA; Payzın KB; Sönmez M; Ayyıldız O; Dal MS; Ertop Ş; Turgut M; Soysal T; Kaya E; Ünal A; Pehlivan M; Atagündüz I; Tuğlular Fıratlı T; Saydam G; Diz Küçükkaya R
    Turk J Haematol; 2019 Nov; 36(4):230-237. PubMed ID: 31327186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience.
    Yaman Y; Elli M; Şahin Ş; Özdilli K; Bilgen H; Bayram N; Nepesov S; Anak S
    Pediatr Transplant; 2021 Aug; 25(5):e13962. PubMed ID: 33452850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin.
    Li Y; Kong F; Bai G; Jiang Y; Zhang W; Sun X; Sui X; Li Y; Ding M; Yuan D; Wang X; Fang X
    Front Immunol; 2024; 15():1340908. PubMed ID: 38650933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herombopag for the treatment of persistent thrombocytopenia following hematopoietic stem cell transplantation.
    Zhou M; Li T; Zhang P; Lai Y; Sheng L; Ouyang G
    Ann Hematol; 2024 May; 103(5):1697-1704. PubMed ID: 38536476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
    Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias.
    Wesson W; Ahmed N; Rashid A; Tabak C; Logan E; Marchena-Burgos J; Nelson M; Davis JA; McGann M; Shune L; Hoffmann M; Abdallah AO; Hashmi H
    Eur J Haematol; 2024 Apr; 112(4):538-546. PubMed ID: 38044594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation.
    Busca A; Dellacasa C; Giaccone L; Manetta S; Biale L; Godio L; Aydin S; Festuccia M; Brunello L; Bruno B
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1765-1770. PubMed ID: 29684566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review.
    Wang XL; Li AM
    Blood Coagul Fibrinolysis; 2016 Oct; 27(7):825-827. PubMed ID: 26650460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem celltransplantation.
    Karataş A; Göker H; Demiroğlu H; Malkan ÜY; Velet M; Çınar OE; Erdoğdu B; Karadeniz M; Sayınalp N; Aksu S; Haznedaroğlu İC; Özcebe Oİ; Büyükaşık Y
    Turk J Med Sci; 2022 Apr; 52(2):413-419. PubMed ID: 36161632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag for the treatment of aplastic anemia: current perspectives.
    Lum SH; Grainger JD
    Drug Des Devel Ther; 2016; 10():2833-2843. PubMed ID: 27695288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.